Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR-T cell combination therapies in hematologic malignancies

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

CAR-T Cell Therapy for Hematological Malignancies: History, Status and Promise

Current progress in CAR-T cell therapy for tumor treatment

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Current state of CAR-T therapy for T-cell malignancies

CAR-T Treatment for Cancer: Prospects and Challenges

CAR-T Cell Therapy: Where Are We Now, and Where Are We Heading?

Application of CAR-T Cell Immunotherapy in the Treatment of Hematological Malignancy

Advances in CAR-T-cell therapy in T-cell malignancies

Chimeric Antigen Receptor T-cell Therapy Beyond Cancer: Current Practice and Future Prospects.